Ignite Creation Date:
2024-05-05 @ 11:57 AM
Last Modification Date:
2024-10-26 @ 9:17 AM
Study NCT ID:
NCT00189709
Status:
COMPLETED
Last Update Posted:
2008-01-02
First Post:
2005-09-12
Brief Title:
Micafungin Versus Fluconazole in the Treatment of Invasive Candidiasis and Candidemia
Sponsor:
Astellas Pharma Inc
Organization:
Astellas Pharma Inc
Study Overview
Official Title:
A Single Center Open Parallel Comparative Randomized Study of Micafungin FK463 vs Fluconazole Diflucan in the Treatment of Invasive Candidiasis and Candidaemia Protocol No MCFGCAN-0301F-TW
Status:
COMPLETED
Status Verified Date:
2007-12
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
To determine the efficacy and safety of micafungin FK463 versus fluconazole Diflucan in treating patients with invasive candidiasis or candidaemia
Detailed Description:
Micafungin a new class of antifungal drugs is compared to fluconazole current standard treatment in the treatment of patients with serious fungal infections invasive candidiasis and candidemia to determine its efficacy and safety Patients both male and female aged over 16 and with confirmed disease by the doctor could be recruited and evaluated
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None